BeyondSpring (NASDAQ:BYSI) Stock Price Passes Below 50 Day Moving Average – Should You Sell?

BeyondSpring Inc. (NASDAQ:BYSI)’s stock price crossed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $1.17 and traded as low as $0.6122. BeyondSpring shares last traded at $0.6205, with a volume of 55,841 shares traded.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of BeyondSpring in a research note on Wednesday, July 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

BeyondSpring Stock Up 2.4%

The stock has a market cap of $25.37 million, a P/E ratio of -5.18 and a beta of 0.48. The business’s 50-day simple moving average is $1.15 and its two-hundred day simple moving average is $1.42.

BeyondSpring (NASDAQ:BYSI) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.52.

Institutional Investors Weigh In On BeyondSpring

A hedge fund recently raised its position in BeyondSpring stock. Geode Capital Management LLC grew its stake in shares of BeyondSpring Inc. (NASDAQ:BYSI) by 951.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 256,212 shares of the company’s stock after acquiring an additional 231,844 shares during the period. Geode Capital Management LLC owned 0.64% of BeyondSpring worth $603,000 at the end of the most recent reporting period. 40.29% of the stock is owned by institutional investors and hedge funds.

BeyondSpring Company Profile

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.